Contact

All Stories

  1. Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE

    Article • Journal of Allergy and Clinical Immunology, February 2022, Elsevier

    Professor Kenneth R Chapman

  2. When less is more in asthma management

    Article • The Journal of Allergy and Clinical Immunology In Practice, December 2021, Elsevier

    Professor Kenneth R Chapman

  3. A tail of two diagnoses: Supporting patients with both COPD and Cardiovascular risks

    Article • October 2021, Springer Science + Business Media

    Professor Kenneth R Chapman

  4. A structured review of the ASCENT Study for COPD

    Article • Advances in Therapy, September 2021, Springer Science + Business Media

    Professor Kenneth R Chapman

  5. Efficacy of MF/IND/GLY to reduce asthma exacerbation

    Article • September 2021, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  6. Pooled data from PALLADIUM and IRIDIUM studies- The impact of Breezhaler® once daily

    Article • BMJ Open Respiratory Research, August 2021, BMJ

    Professor Kenneth R Chapman

  7. The cause of COPD is not always smoking history.

    Article • American Journal of Respiratory and Critical Care Medicine, June 2021, American Thoracic Society

    Professor Kenneth R Chapman

  8. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2021, Taylor & Francis

    Professor Kenneth R Chapman

  9. The experience of asthma from the patient and physicians

    Article • Respiratory Medicine, June 2021, Elsevier

    Professor Kenneth R Chapman

  10. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

    Article • May 2021, Springer Science + Business Media

    Professor Kenneth R Chapman

  11. The survey for Asthma Patients’ and Physicians’ Perspectives on the Burden and Management of Asthma

    Article • May 2021, American Thoracic Society

    Professor Kenneth R Chapman

  12. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2021, Taylor & Francis

    Professor Kenneth R Chapman

  13. The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2021, Taylor & Francis

    Professor Kenneth R Chapman

  14. A review of the past, present and future for Alpha-1 Antitrypsin Deficiency

    Article • American Journal of Respiratory Cell and Molecular Biology, October 2020, American Thoracic Society

    Professor Kenneth R Chapman

  15. Reducing the hidden burden of severe asthma: recognition and referrals from primary practice

    Article • Journal of Asthma, May 2020, Taylor & Francis

    Professor Kenneth R Chapman

  16. Working smarter to improve asthma care

    Article • May 2020, American Thoracic Society

    Professor Kenneth R Chapman

  17. Status of Severe Asthma Management in Canada

    Article • Canadian Journal of Respiratory Critical Care and Sleep Medicine, December 2019, Taylor & Francis

    Professor Kenneth R Chapman, Erika Penz

  18. Treatment of Asthma with Breezhaler

    Article • September 2019, European Respiratory Society (ERS)

    Kenneth Chapman, Professor Kenneth R Chapman

  19. Long term impacts of tobacco and marijuana smoking on lung function

    Article • European Respiratory Journal, September 2019, European Respiratory Society (ERS)

    wan tan, Professor Kenneth R Chapman

  20. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD

    Article • European Respiratory Journal, August 2019, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  21. Improving maintenance treatment for COPD patients

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2019, Dove Medical Press

    Professor Kenneth R Chapman, driss rochdi, Andrew McIvor

  22. COPD exacerbation rates with IND/GLY

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2018, Dove Medical Press

    Claus Vogelmeier, Professor Kenneth R Chapman, Dr. Konstantinos Kostikas, Jørgen Vestbo

  23. An update on Alpha 1 antitrypsin deficiency

    Article • International Journal of Chronic Obstructive Pulmonary Disease, January 2018, Dove Medical Press

    Professor Kenneth R Chapman, Rembert Koczulla, Noel G McElvaney

  24. Self-Management and Clinical Decision Support for Patients With Complex Chronic Conditions Through the Use of Smartphone-Based Telemonitoring: Randomized Controlled Trial Protocol

    Article • JMIR Research Protocols, November 2017, JMIR Publications Inc.

    Professor Kenneth R Chapman

  25. A review of COPD from the 2015 European Respiratory Society Congress

    Article • Respiratory Medicine, March 2016, Elsevier

    Professor Kenneth R Chapman

  26. Safety of Breezhaler® device

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2015, Dove Medical Press

    Professor Kenneth R Chapman, Pankaj Goyal

  27. The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued

    Article • Respiratory Medicine, March 2015, Elsevier

    Professor Kenneth R Chapman

  28. Clinical Relevance of Fixed Ratio vs Lower Limit of Normal of FEV1/FVC in COPD: Patient-Reported Outcomes From the CanCOLD Cohort

    Article • The Annals of Family Medicine, January 2015, Annals of Family Medicine

    Professor Kenneth R Chapman

  29. Exacerbations in non-COPD patients: truth or myth—authors’ response

    Article • Thorax, July 2014, BMJ

    Professor Kenneth R Chapman

  30. Quality Assurance of Spirometry in a Population-Based Study –Predictors of Good Outcome in Spirometry Testing

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, March 2014, Taylor & Francis

    Professor Kenneth R Chapman

  31. Comparing the standard COPD drug treatment to a new drug: Tiotropium VS. Glycopyrronium

    Article • BMC Pulmonary Medicine, January 2014, Springer Science + Business Media

    Professor Kenneth R Chapman

  32. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries

    Article • Journal of Asthma, November 2013, Taylor & Francis

    Professor Kenneth R Chapman

  33. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study

    Article • Respiratory Medicine, October 2013, Elsevier

    Professor Kenneth R Chapman

  34. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

    Article • The Lancet Respiratory Medicine, September 2013, Elsevier

    Professor Peter Anthony Frith, Professor Kenneth R Chapman

  35. Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, March 2013, Taylor & Francis

    Professor Kenneth R Chapman

  36. Bronchodilator Responsiveness and Reported Respiratory Symptoms in an Adult Population

    Article • PLoS ONE, March 2013, PLOS

    Professor Kenneth R Chapman

  37. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach

    Article • Orphanet Journal of Rare Diseases, January 2013, Springer Science + Business Media

    Professor Kenneth R Chapman

  38. Asthma controller delay and recurrence risk after an emergency department visit or hospitalization

    Article • Respiratory Medicine, December 2012, Elsevier

    Professor Kenneth R Chapman

  39. What Do We Know about Asthma Triggers? A Review of the Literature

    Article • Journal of Asthma, November 2012, Taylor & Francis

    Professor Kenneth R Chapman

  40. A Step Forward in COPD Management

    Article • CHEST Journal, November 2012, Elsevier

    Professor Kenneth R Chapman

  41. Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease

    Article • Canadian Medical Association Journal, July 2012, Canadian Medical Association (CMA)

    Professor Kenneth R Chapman

  42. The Association Between Chronic Exposure to Traffic-Related Air Pollution and Ischemic Heart Disease

    Article • Journal of Toxicology and Environmental Health Part A, April 2012, Taylor & Francis

    Professor Kenneth R Chapman

  43. Profile of eicosanoids in breath condensate in asthma and COPD

    Article • Journal of Breath Research, March 2012, Institute of Physics Publishing

    Professor Kenneth R Chapman

  44. Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, March 2012, Taylor & Francis

    Professor Kenneth R Chapman

  45. Improved outcomes and adherence with novel COPD treatment: Indacaterol

    Article • International Journal of Chronic Obstructive Pulmonary Disease, March 2012, Taylor & Francis

    Professor Kenneth R Chapman

  46. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor

    Article • European Respiratory Journal, January 2012, European Respiratory Society (ERS)

    Professor Kenneth R Chapman

  47. The SMART treatment for asthma isn't as smart as it seems

    Article • Clinical & Experimental Allergy, January 2012, Wiley

    Professor Kenneth R Chapman

  48. Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada

    Article • The International Journal of Tuberculosis and Lung Disease, December 2011, International Union Against Tuberculosis and Lung Disease

    Professor Kenneth R Chapman

  49. Long-term Safety and Efficacy of Indacaterol, a Long-Acting β 2 -Agonist, in Subjects With COPD

    Article • CHEST Journal, July 2011, Elsevier

    Professor Kenneth R Chapman

  50. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2011, Taylor & Francis

    Professor Kenneth R Chapman

  51. Nontuberculous Mycobacterial Infection as a Cause of Difficult-to-Control Asthma

    Article • CHEST Journal, January 2011, Elsevier

    Professor Kenneth R Chapman

  52. Infection with Mycoplasma pneumoniae is not related to asthma control, asthma severity, and location of airway obstruction

    Article • International Journal of General Medicine, December 2010, Taylor & Francis

    Kamyar Ghabili, Professor Reza Ghotaslou, Professor Kenneth R Chapman

  53. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study

    Article • BMC Clinical Pharmacology, September 2010, Springer Science + Business Media

    Professor Kenneth R Chapman

  54. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal

    Article • Thorax, June 2010, BMJ

    Professor Kenneth R Chapman

  55. Dynamic Airway Evaluation with Volume CT: Initial Experience

    Article • Canadian Association of Radiologists Journal, April 2010, SAGE Publications

    Professor Kenneth R Chapman

  56. Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma

    Article • Respiratory Medicine, April 2010, Elsevier

    Professor Kenneth R Chapman

  57. SMART isn't

    Article • Journal of Allergy and Clinical Immunology, March 2010, Elsevier

    Professor Kenneth R Chapman

  58. Asthma that is unresponsive to usual care

    Article • Canadian Medical Association Journal, October 2009, Canadian Medical Association (CMA)

    Professor Kenneth R Chapman